{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:55:46Z","timestamp":1791932146743,"version":"4.3.4"},"reference-count":31,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To estimate the incidence, prevalence, patient characteristics and healthcare utilization patterns of moderate to severe thyroid eye disease (TED) in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective review of medical and prescription claims data from the Inovalon deidentified claims database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients<\/jats:title>\n                    <jats:p>\n                      Patients with moderate to severe TED were identified based on specific and sensitive definitions using\n                      <jats:italic>International Classification of Diseases<\/jats:italic>\n                      (ICD) codes selected by a group of TED specialists.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The incident moderate to severe TED population included 3364 and 1730 patients using the sensitive and specific definitions, respectively. After adjusting for age and gender, corresponding incidence rates in the sensitive and specific populations were 8.97 (13.49 in women and 4.27 in men) and 4.37 (6.59 in women and 2.05 in men) per 100,000 person\u2010years, respectively. The prevalent population included 16,310 and 8018 patients using the sensitive and specific definitions, respectively, corresponding to adjusted prevalence rates of 44.13 (66.00 in women and 21.39 in men) and 20.55 (31.18 in women and 9.50 in men) per 100,000 persons. A preponderance of women was observed, and comorbidity rates were high, with &gt;\u200940% of prevalent patients experiencing hypertension. Steroids were the most frequently prescribed medication. The impact of teprotumumab was not captured, since this study only included claims data through 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The estimated incidence and prevalence rates of TED demonstrate the considerable impact of this disease in the United States, making the creation of a specific ICD code imperative for effective healthcare planning and management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/cen.15183","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T02:54:52Z","timestamp":1734490492000},"page":"482-489","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Epidemiology and Management of Moderate to Severe Thyroid Eye Disease in the United States: Analysis of a Healthcare Claims Database"],"prefix":"10.1111","volume":"102","author":[{"given":"Marius N.","family":"Stan","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilly H.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Mayo Clinic Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kharisa N.","family":"Rachmasari","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Venker","sequence":"additional","affiliation":[{"name":"Roivant Sciences New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Arackal","sequence":"additional","affiliation":[{"name":"University of Health Sciences and Pharmacy St Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Roivant Sciences New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley\u2010Ann","family":"Miller\u2010Wilson","sequence":"additional","affiliation":[{"name":"Immunovant Inc. New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Schwinn","sequence":"additional","affiliation":[{"name":"Immunovant Inc. New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Mina\u2010Osorio","sequence":"additional","affiliation":[{"name":"Immunovant Inc. New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7453260"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e3283499446"},{"key":"e_1_2_9_4_1","unstructured":"TEPEZZA (teprotumumab\u2010trbw) for Injection for Intravenous Use. Prescribing Information. Horizon Therapeutics; 2023 accessed December 5 2023 https:\/\/www.hzndocs.com\/TEPEZZA-Prescribing-Information.pdf."},{"key":"e_1_2_9_5_1","unstructured":"FDA Approves First Treatment for Thyroid Eye Disease.News Release. U.S. Food and Drug Administration. January 21 2020 accessed December 5 2023 https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-thyroid-eye-disease."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2023.1295902"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.1002"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0625-1"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad114.1886"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.615993"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1275"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)72666-2"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2023.04.013"},{"key":"e_1_2_9_14_1","unstructured":"X.Chen R.Silkiss O.Idowu Z.Haskova L.Adesanya andP.DayalPrevalence of Thyroid Eye Disease in the US: A Real\u2010World Data Study. Presented at the American Thyroid Association Annual Meeting September 27\u2013October 1 2023;Washington DC."},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13899"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab034"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0548"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-306733"},{"issue":"4","key":"e_1_2_9_19_1","first-page":"343","article-title":"Thyroid Eye Disease","volume":"119","author":"Szelog J.","year":"2022","journal-title":"Missouri Medicine"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S193018"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1993.tb00516.x"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/1120672120964112"},{"key":"e_1_2_9_23_1","first-page":"477","article-title":"The Epidemiologic Characteristics and Clinical Course of Ophthalmopathy Associated With Autoimmune Thyroid Disease in Olmsted County, Minnesota","volume":"92","author":"Bartley G. B.","year":"1994","journal-title":"Transactions of the American Ophthalmological Society"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S61041"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1402"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2015.76"},{"issue":"1","key":"e_1_2_9_27_1","first-page":"A75","article-title":"Comorbidities and Thyroid Eye Disease Severity: Which Factors Are Most Commonly Associated With More Severe Disease","volume":"31","author":"Cockerham K.","year":"2021","journal-title":"Thyroid"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1159\/000475969"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_104_20"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad148"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/life12122084"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0148"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cen.15183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T06:58:50Z","timestamp":1741589930000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cen.15183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1111\/cen.15183"],"URL":"https:\/\/doi.org\/10.1111\/cen.15183","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,17]]},"assertion":[{"value":"2024-08-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}